

Information for Connecticut Prescribers of Prescription Drugs
Provided Pursuant to the State of Connecticut's
Substitute House Bill No. 6669
Public Act No. 23-171

Tecentriq Hybreza™
(atezolizumab-hyaluronidase-tqjs)

<u>Legend Drug</u>	<u>WAC Unit Price*</u>	<u>WAC Package Price*</u>
Tecentriq Hybreza 1,875 mg - 30,000 unit/15 mL Vial	\$ 750.12066 per mL	\$ 11,251.81 per vial

Listed price(s) is/are based on the dose and quantity of the drug as described in the US Prescribing Informations (USPI).

Information on the variation efficacy of the legend drug marketed in different racial and ethnic groups is included in the US Prescribing Information (USPI), if any such information is available and meets the standard for including in the USPI per Food and Drug Administration regulations.

**Wholesale Acquisition Cost (WAC) as published by FDB represents the manufacturer's published catalog or list price for a drug product to wholesalers as reported to FDB by the manufacturer. WAC does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price. FDB does not perform any independent investigation or analysis of actual transaction prices for purposes of reporting WAC. FDB relies on manufacturers to report or otherwise make available the values for the WAC.*

For more information about First Databank's drug pricing policy, visit
<https://www.fdbhealth.com/drug-pricing-policy>

Source: AnalySource® 01/01/2025 as reprinted with permission by First Databank, Inc. All rights reserved. ©2025